Results 81 to 90 of about 50,656 (201)

Tinjauan atas Glucagon-like peptide-1 receptor agonist

Cermin Dunia Kedokteran, 2020
<p>GLP-1 receptor agonist secara struktur mirip hormon alami GLP-1 yang memiliki efek incretin, namun degradasinya dapat dicegah oleh DPP-4. Saat ini terdapat 8 jenis yang terdiri dari exenatide, exenatide ER, liraglutide, albiglutide, dulaglutide, lixisenatide, semaglutide injeksi, dan semaglitode oral.
openaire   +1 more source

Glucagon-like peptide-1 receptor agonists and muscle mass effects

Pharmacological Research
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of obesity, demonstrating significant efficacy in inducing weight loss and improving metabolic parameters. However, emerging clinical and paraclinical evidence suggests
Alexandr Ceasovschih, Andreea Asaftei, Maria Giovanna Lupo, Stanislav Kotlyarov, Hana Bartušková, Anastasia Balta, Victorita Sorodoc, Laurentiu Sorodoc, Maciej Banach   +8 more
doaj   +1 more source

Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors [PDF]

, 2009
BACKGROUND: Type 2 diabetes is a chronic, progressive disease with a multi-faceted pathophysiology. Beyond the known defects of insulin resistance and beta-cell insufficiency, derangement of incretin hormones normally produced from the gut wall in ...
Berneis, K, Rini, G B, Rizvi, A A, Rizzo, M, Spinas, G A   +4 more
core   +1 more source

SCFAs strongly stimulate PYY production in human enteroendocrine cells. [PDF]

, 2018
Peptide-YY (PYY) and Glucagon-Like Peptide-1 (GLP-1) play important roles in the regulation of food intake and insulin secretion, and are of translational interest in the field of obesity and diabetes.
Blottiere, HM, Dore, J, Gribble, FM, Lapaque, N, Larraufie, P, Martin-Gallausiaux, C, Reimann, F   +6 more
core   +3 more sources

Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?

Therapeutics and Clinical Risk Management, 2022
Tanzila S Razzaki,* Alyson Weiner,* Alpana P Shukla Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism Weill Cornell Medicine, New York, NY, USA*These authors contributed equally to this ...
Razzaki TS, Weiner A, Shukla AP
doaj  

Metformin Versus GLP-1 for Therapeutic Potential in Polycystic Ovary Syndrome [PDF]

Purpose: When patients with polycystic ovary syndrome fail conservative options for weight loss, utilizing medications such as metformin and glucagon-like peptide-1 receptor agonists may be considered. Metformin has been the first line agent for treating
Stone, Carlyn
core   +1 more source

Glucagon‐like peptide‐1 receptor agonists for type 2 diabetes: A rational drug development

Journal of Diabetes Investigation, 2019
Today, glucagon‐like peptide‐1 (GLP‐1) receptor agonists are established glucose‐lowering drugs used in the management of type 2 diabetes. Their development emerged from the understanding that a combined islet dysfunction comprising of impaired insulin ...
Bo Ahrén
doaj   +1 more source

Integrative gene-metabolite network analysis of GLP-1 receptor agonists and related incretin pathways in cardiometabolic health

npj Systems Biology and Applications
Glucagon-like peptide-1 (GLP-1) is a hormone known for its critical functions in managing blood sugar and offering cardiovascular benefits. Our study focuses on Glucagon Like Peptide 1 Receptor (GLP1R) agonists that act beyond glycemic control in ...
Zofia Wicik, Anna Nowak-Szwed, Ceren Eyileten, Harald Sourij, Dirk von Lewinski, Svjatoslavs Kistkins, Joanna Borkowska, Marek Postuła   +7 more
doaj   +1 more source

Glucagon Receptor Antagonism Ameliorates Progression of Heart Failure. [PDF]

, 2019
Mice were treated with a fully human monoclonal glucagon receptor antagonistic antibody REMD2.59 following myocardial infarction or pressure overload.
Baal, Ulysis, Gao, Chen, Lu, John, Ren, Shuxun Vincent, Thai, Dung, Wang, Yibin, Yan, Hai, Yu, Junyi, Zeng, Chunyu   +8 more
core  

Glucagon-like peptide-1 receptor agonists: Prospects for use in rheumatology

Научно-практическая ревматология
Glucagon-like peptide-1 receptor agonists (ArGLP-1) are effective drugs for the treatment of type 2 diabetes mellitus and obesity. Recent studies in patients with a wide range of immunoinflammatory diseases suggest important pleiotropic mechanisms of ...
Е. L. Nasonov, Т. S. Panevin, Е. А. Troshina   +2 more
doaj   +1 more source